Antibacterial and antibiofilm efficacy of synthetic polymyxin‐mimetic lipopeptides. Issue 1 (12th September 2020)

• Record Type: Journal Article
• Authors: Huwaitat, Rawan; Coulter, Sophie M.; Porter, Simon L.; Pentlavalli, Sreekanth; Laverty, Garry
• Other Names: Jamieson Andrew G. guestEditor.
• Is Part Of: Peptide science. Volume 113:Issue 1(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-09-12
• Subjects: antibacterial -- antimicrobial peptides -- antimicrobial resistance -- biofilm -- nosocomial infection -- peptides; Peptides -- Periodicals; 572.6505
• DOI: 10.1002/pep2.24188
• Languages: English
• ISSNs: 2475-8817

Abstract

Abstract: The increasing emergence of multidrug‐resistant bacteria is a huge problem to society providing significant risks to public health. This has been further escalated by a decline in the clinical translation of new antibacterial drug classes since the 1980s. In this article, we describe the synthesis, antibacterial/antibiofilm activity and in vitro toxicity of synthetic low molecular weight lipopeptides mimetics of polymyxin. C12 ‐KTKCKFLKKC‐NH2 and C14 ‐KTKCKFLKKC‐NH2 lipopeptides demonstrated activity against both planktonic and biofilm forms of Staphylococcus epidermidis, Staphylococcus aureus, MRSA, Escherichia coli, and Acinetobacter baumannii . Peptide‐outer membrane interaction was studied using lipopolysaccharide neutralization and N‐phenyl‐1‐napthylamine assays. C12 ‐conjugated peptide significantly neutralized lipopolysaccharide at concentrations lower than minimum inhibitory concentration values against Gram‐negative E coli, by an average of 90% and demonstrated up to double the outer membrane permeabilization ability of 10 mg/mL polymyxin B. Polymyxin‐mimetic lipopeptides have the potential to undergo further in vitro and in vivo study to enable clinical translation and help alleviate the current antimicrobial crisis. Abstract :